This combination medication contains Sitagliptin Phosphate Monohydrate 100mg and Dapagliflozin Propanediol Monohydrate 10mg, formulated for the management of type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor that enhances incretin hormones, increasing insulin release and decreasing glucagon levels, helping control blood sugar. Dapagliflozin is an SGLT2 inhibitor that works by promoting the excretion of excess glucose through urine, reducing hyperglycemia. Together, they provide dual action for better glycemic control, reduce the risk of cardiovascular events in diabetic patients, and may aid in weight management. This combination is ideal for patients whose blood sugar levels are not adequately controlled by diet, exercise, or monotherapy, providing a convenient once-daily oral dosage.
